Next Article in Journal
Vaccination Criteria Based on Factors Influencing COVID-19 Diffusion and Mortality
Next Article in Special Issue
Immune Complex Vaccine Strategies to Combat HIV-1 and Other Infectious Diseases
Previous Article in Journal
A Comprehensive Review of the Immunological Response against Foot-and-Mouth Disease Virus Infection and Its Evasion Mechanisms
Previous Article in Special Issue
Frequent and Durable Anti-HIV Envelope VIV2 IgG Responses Induced by HIV-1 DNA Priming and HIV-MVA Boosting in Healthy Tanzanian Volunteers
Open AccessArticle

Virus-Like Particle Based Vaccines Elicit Neutralizing Antibodies against the HIV-1 Fusion Peptide

1
Department of Molecular Genetics and Microbiology, University of New Mexico, Albuquerque, NM 87131, USA
2
Aaron Diamond AIDS Research Center, New York, NY 10016, USA
3
Department of Medicine, Columbia University Irving Medical Center, New York, NY 10032, USA
4
Vaccine Research Center, NIAID, NIH, 40 Convent Drive, Bethesda, MD 20892, USA
*
Authors to whom correspondence should be addressed.
Vaccines 2020, 8(4), 765; https://doi.org/10.3390/vaccines8040765
Received: 4 November 2020 / Revised: 11 December 2020 / Accepted: 11 December 2020 / Published: 15 December 2020
(This article belongs to the Special Issue HIV Vaccine)
Broadly neutralizing antibodies (bnAbs) isolated from HIV-infected individuals delineate vulnerable sites on the HIV envelope glycoprotein that are potential vaccine targets. A linear epitope within the N-terminal region of the HIV-1 fusion peptide (FP8) is the primary target of VRC34.01, a bnAb that neutralizes ~50% of primary HIV isolates. FP8 has attracted attention as a potential HIV vaccine target because it is a simple linear epitope. Here, platform technologies based on RNA bacteriophage virus-like particles (VLPs) were used to develop multivalent vaccines targeting the FP8 epitope. Both recombinant MS2 VLPs displaying the FP8 peptide and Qβ VLPs displaying chemically conjugated FP8 peptide induced high titers of FP8-specific antibodies in mice. Moreover, a heterologous prime-boost-boost regimen employing the two FP8-VLP vaccines and native envelope trimer was the most effective approach for eliciting HIV-1 neutralizing antibodies. Given the potent immunogenicity of VLP-based vaccines, this vaccination strategy—inspired by bnAb-guided epitope mapping, VLP bioengineering, and prime-boost immunization approaches—may be a useful strategy for eliciting bnAb responses against HIV. View Full-Text
Keywords: broadly neutralizing antibody; HIV-1 fusion peptide; HIV-1 DS-SOSIP trimer; prime-boost immunizations; vaccine; virus-like particles broadly neutralizing antibody; HIV-1 fusion peptide; HIV-1 DS-SOSIP trimer; prime-boost immunizations; vaccine; virus-like particles
Show Figures

Figure 1

MDPI and ACS Style

Mogus, A.T.; Liu, L.; Jia, M.; Ajayi, D.T.; Xu, K.; Kong, R.; Huang, J.; Yu, J.; Kwong, P.D.; Mascola, J.R.; Ho, D.D.; Tsuji, M.; Chackerian, B. Virus-Like Particle Based Vaccines Elicit Neutralizing Antibodies against the HIV-1 Fusion Peptide. Vaccines 2020, 8, 765. https://doi.org/10.3390/vaccines8040765

AMA Style

Mogus AT, Liu L, Jia M, Ajayi DT, Xu K, Kong R, Huang J, Yu J, Kwong PD, Mascola JR, Ho DD, Tsuji M, Chackerian B. Virus-Like Particle Based Vaccines Elicit Neutralizing Antibodies against the HIV-1 Fusion Peptide. Vaccines. 2020; 8(4):765. https://doi.org/10.3390/vaccines8040765

Chicago/Turabian Style

Mogus, Alemu T.; Liu, Lihong; Jia, Manxue; Ajayi, Diane T.; Xu, Kai; Kong, Rui; Huang, Jing; Yu, Jian; Kwong, Peter D.; Mascola, John R.; Ho, David D.; Tsuji, Moriya; Chackerian, Bryce. 2020. "Virus-Like Particle Based Vaccines Elicit Neutralizing Antibodies against the HIV-1 Fusion Peptide" Vaccines 8, no. 4: 765. https://doi.org/10.3390/vaccines8040765

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop